Gyre Therapeutics (GYRE) Gross Profit (2020 - 2026)

Gyre Therapeutics (GYRE) has 7 years of Gross Profit data on file, last reported at $8.4 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $8.4 million, down 60.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.6 million (down 60.11% YoY), and the FY2025 annual result was $51.4 million, down 49.54% from the prior year.
• Gross Profit rose to $8.4 million in Q1 2026 per GYRE's latest filing, from -$24.3 million in the prior quarter.
• Over five years, Gross Profit peaked at $48.1 million in Q4 2022 and troughed at -$24.3 million in Q4 2025.
• A 5-year average of $21.2 million and a median of $25.6 million in 2025 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2023 and 2025: Gross Profit jumped 595250.0% in 2023, then tumbled 191.07% in 2025.
• A 5-year view of Gross Profit shows it stood at $48.1 million in 2022, then plunged by 46.11% to $25.9 million in 2023, then advanced by 3.08% to $26.7 million in 2024, then plunged by 191.07% to -$24.3 million in 2025, then surged by 134.48% to $8.4 million in 2026.
• Business Quant data shows GYRE's Gross Profit at $8.4 million in Q1 2026, -$24.3 million in Q4 2025, and $28.9 million in Q3 2025.